Composition
- Active ingredients
- DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 1GM; SAXAGLIPTIN HYDROCHLORIDE EQ 5MG BASE
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 1GM; SAXAGLIPTIN HYDROCHLORIDE EQ 5MG BASE · Tablet, extended releaseThis page
- DAPAGLIFLOZIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM; SAXAGLIPTIN HYDROCHLORIDE EQ 2.5MG BASE · Tablet, extended releaseNDA210874-001 · Discontinued
- DAPAGLIFLOZIN 10MG; METFORMIN HYDROCHLORIDE 1GM; SAXAGLIPTIN HYDROCHLORIDE EQ 5MG BASE · Tablet, extended releaseNDA210874-004 · Discontinued
- DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 1GM; SAXAGLIPTIN HYDROCHLORIDE EQ 2.5MG BASE · Tablet, extended releaseNDA210874-002 · Discontinued
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA210874.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Qternmet XR
- Active substance
- dapagliflozin
- Route
- Oral
- Dosage form
- Tablet, extended release
- Applicant
- Astrazeneca AB
- Status
- Discontinued
- FDA approval
- 2 May 2019
- Application
- NDA210874-003